Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
None listed
Sponsors
GCSMCH&RC
Eligibility
Inclusion criteria
Inclusion criteria: all patients with clinically diagnosed and confirmed with KOH smear examination for tinea/ dermatophytic infection with age 18-60 years who are willing to sign informed consent form.
Exclusion criteria
Exclusion criteria: A. Patients who are not willing to sign informed consent form. B. Patients with age less than 18 years and more than 60 years. C. Pregnant and lactating mothers. D. Patients with diseases enlisted in point E&F which may interfere with expression of IL-17 in tissue. E. Cutaneous disorders like- acne, hidradenitis suppurativa, psoriasis, alopecia areata, vitiligo, autoimmune bullous diseases F. Systemic diseases like- multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus, asthma, Behcet’s disease, hyper IgE syndrome, systemic sclerosis G. Preexisting Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal,endocrine, immunologic, musculoskeletal, neurological, or psychiatric disease. H. Major surgical or medical illness in last 4 weeks before screening, Any concomitant medication for purpose other than dermatophytosis management at presentation or within last 4 weeks before screening. I. Any concomitant intake of herbal, homeopathic or other alternative therapy at presentation or within last 4 weeks before screening. J. Alcohol dependence, alcohol abuse or drug abuse within the past year. K. Moderate to heavy smoking ( >10 cigarettes/day) or consumption of tobacco products L. Clinically significant illness within 4 weeks before the start of the study M. Asthma, urticaria or other allergic type reactions after taking any medication. N. Patient having pre-existing medical condition (DM HT or any other medical condition requiring concomitant medicine.) or diagnosed during screening. O. Dermatophytosis independently involving scalp (T. Capitis), nail, palm (T. pedis) and sole (T. mannum). P. Patients having skin lesions with secondary bacterial infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •To estimate the expression of IL-17 in skin tissue of patients with dermatophytosisTimepoint: •single point, at base line | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To estimate the correlation of expression of IL-17 in skin tissue with various clinical parameters like, duration of disease, morphology of lesions & steroid exposure etc. 2. To estimate the correlation of expression of IL-17 in skin tissue of patients with various histopathological parameters like epidermal hyperplasia, presence of neutrophils, etc. 3. To estimate the pathological reaction patterns & its corelation with clinical parameters in tissue samples of dermatophytosis. Timepoint: single point, at baseline | — |
Countries
India
Contacts
Public ContactJignaben Krunal Padhiyar
GCSMCH&RC
Outcome results
None listed